Loading stock data…
BYSI
$1.72+0.02 (+1.18%)
Market ClosedLast close Jun 9
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BeyondSpring Inc. in the Healthcare sector is trading at $1.72. The stock is currently 50% below its 52-week high of $3.44, remaining 0.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.72
Potential Downside
0%
Whystock Fair Value$1.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.16%
Volume
Today's trading volume
15,616
Recent News
BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)
Shares of BeyondSpring (NASDAQ:BYSI) climbed more than 6% in premarket trading on Wednesday after the company reported a smaller loss from continuing operations and highlighted progress across its development pipeline. The stock gained 6.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26% to $6.33. The market value of their outstanding shares is at $963.2 million. The company's, Q1 earnings came out yesterday. Whitehawk Therapeutics (NASDAQ:WHWK) stock rose 20.17% to $4.71. The market value of their outstanding shares is at $193.8 million. As per
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...